# US 2021/0277470 A1 · Methods and compositions for enriching non-host sequences in host samples

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277470 A1
- Document ID: US20210277470A1
- Status: Published application
- Kind: A1
- Application number: 17/330,338
- Filed: 2021-05-25
- Published: 2021-09-09
- Earliest claimed: 2013-12-04
- Assignees: University of Alaska Fairbanks
- Applicants: University of Alaska Fairbanks
- Inventors: Jiguo Chen; Fang Ge
- Web page: https://patentgrep.com/patent/US20210277470A1

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6888: for detection or identification of organisms
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are compositions and methods for enriching a non-host sequence from a host sample. Also disclosed are compositions and methods for detecting a non-host sequence in a host sample. For example, a pathogen can be enriched and detected in a sample taken from a human without knowing what the pathogen is.

## Claims

### Claim at position 1

-74. (canceled)

### Claim 75

A method of enriching non-human nucleic acids from a human sample comprising selectively amplifying nucleic acids isolated from the human sample using non-human target primers to form an enriched population of non-human nucleic acids, wherein the non-human target primers do not bind to at least the top 1,000 human B cell transcripts.

### Claim 76 (depends on 75)

The method of claim 75, wherein the nucleic acids isolated from the human sample are selected from the group consisting of DNA and RNA.

### Claim 77 (depends on 75)

The method of claim 75 further comprising performing subtractive hybridization against a population of reference human cDNAs, wherein the subtractive hybridization results in a further enriched population of non-human nucleic acids.

### Claim 78 (depends on 75)

The method of claim 75, wherein the top 1,000 human B cell transcripts comprise at least 65% of all human B cell transcripts.

### Claim 79 (depends on 75)

The method of claim 75, wherein the top 1,000 human B cell transcripts are greater than 200 base pairs in length.

### Claim 80 (depends on 75)

The method of claim 75, wherein the non-human target primers do not bind to at least the top 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000 human B cell transcripts or whole human B cell transcriptome.

### Claim 81 (depends on 75)

The method of claim 75, wherein the non-human nucleic acids are pathogenic sequences.

### Claim 82 (depends on 81)

The method of claim 81, wherein the pathogenic sequences are from viruses, bacteria, fungi, or any infectious agents.

### Claim 83

A method of enriching non-human nucleic acids from a human sample comprising hybridizing a set of non-human target primers to total RNA or mRNA isolated from the human sample and selectively reverse transcribing total RNA or mRNA isolated from the human sample to form an enriched population of non-human cDNA strands, wherein the set of non-human target primers do not hybridize to at least the top 1,000 human B cell transcripts.

### Claim 84 (depends on 83)

The method of claim 83 further comprising performing subtractive hybridization against a population of reference human cDNAs, wherein the subtractive hybridization results in a further enriched population of non-human cDNAs.

### Claim 85 (depends on 83)

The method of claim 83, wherein the top 1,000 human transcripts comprise at least 65% of all human B cell transcripts.

### Claim 86 (depends on 83)

The method of claim 83, wherein the top 1,000 human B cell transcripts are greater than 200 base pairs in length.

### Claim 87 (depends on 83)

The method of claim 83, wherein the non-human target primers do not bind to at least the top 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000 human transcripts or whole human transcriptome.

### Claim 88 (depends on 83)

The method of claim 83, wherein the non-human nucleic acids are pathogenic sequences.

### Claim 89 (depends on 88)

The method of claim 88, wherein the pathogenic sequences are from viruses, bacteria, fungi, or any infectious agents.

### Claim 90

A diagnostic assay, comprising non-human target primers for amplifying nucleic acids from a human sample to form an enriched population of non-human nucleic acids, wherein the non-human target primers do not bind to at least the top 1,000 human B cell transcripts.

### Claim 91 (depends on 90)

The assay of claim 90, wherein the top 1,000 human B cell transcripts comprise at least 65% of all human B cell transcripts.

### Claim 92 (depends on 90)

The assay of claim 90, wherein the top 1,000 human B cell transcripts are greater than 200 base pairs in length.

### Claim 93 (depends on 90)

The assay of claim 90, wherein the non-human target primers do not bind to at least the top 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000 human B cell transcripts or whole human B cell transcriptome.

### Claim 94 (depends on 90)

The assay of claim 90, wherein the non-human target primers are at least the oligonucleotides in FIG. 10 or FIG. 11.
